Royalty Pharma plc (RPRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 9.41%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.86%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9.41% | Research and development expense / revenue. Period ending 2026-06-30. $238.64M ÷ $2.54B × 100 ≈ 9.41% |
| Stock-based compensation / revenue · 12 months | 16.86% | Share-based compensation / revenue. Period ending 2026-06-30. $427.67M ÷ $2.54B × 100 ≈ 16.86% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 238.64M USD | Research and Development Expense |
| Revenue | 2.54B USD | |
| Stock-based compensation | 427.67M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.51B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $238.64M | $2.54B | $427.67M | $1.51B | (m) | 9.41% | 16.86% | (m) | (m) |
| 2026-03-31 | $441.29M | $2.44B | $411.37M | $1.59B | (m) | 18.08% | 16.86% | (m) | (m) |
| 2025-12-31 | $452.00M | $2.38B | $289.89M | $1.56B | (m) | 19.01% | 12.19% | (m) | (m) |
| 2025-09-30 | $402.00M | $2.35B | $164.65M | $1.53B | (m) | 17.11% | 7.01% | (m) | (m) |
| 2025-06-30 | $352.00M | $2.31B | $92.33M | $1.84B | (m) | 15.27% | 4.01% | (m) | (m) |
| 2025-03-31 | $52.00M | $2.26B | $2.25M | $1.90B | (m) | 2.30% | 0.10% | (m) | (m) |
| 2024-12-31 | $2.00M | $2.26B | $2.34M | $1.29B | (m) | 0.09% | 0.10% | (m) | (m) |
| 2024-09-30 | $2.00M | $2.27B | $2.44M | $1.54B | (m) | 0.09% | 0.11% | (m) | (m) |
| 2024-06-30 | $52.00M | $2.24B | $2.49M | $960.19M | (m) | 2.32% | 0.11% | (m) | (m) |
| 2024-03-31 | $52.00M | $2.24B | $2.40M | $939.40M | $184.47M | 2.32% | 0.11% | 5.09× | Reported |
| 2023-12-31 | $52.00M | $2.35B | $2.36M | $1.49B | $187.19M | 2.21% | 0.10% | 7.97× | Reported |
| 2023-09-30 | $102.00M | $2.32B | $2.32M | $396.60M | $186.89M | 4.39% | 0.10% | 2.12× | Reported |
| 2023-06-30 | $77.00M | $2.36B | $2.32M | $437.37M | $187.83M | 3.26% | 0.10% | 2.33× | Reported |
| 2023-03-31 | $77.11M | $2.36B | $2.25M | $566.32M | $187.85M | 3.27% | 0.10% | 3.01× | Reported |
| 2022-12-31 | $177.11M | $2.24B | $2.17M | $307.06M | $187.96M | 7.92% | 0.10% | 1.63× | Reported |
| 2022-09-30 | $230.43M | $2.25B | $2.09M | $943.14M | $187.98M | 10.25% | 0.09% | 5.02× | Reported |
| 2022-06-30 | $295.43M | $2.26B | $2.01M | $1.05B | $185.33M | 13.08% | 0.09% | 5.69× | Reported |
| 2022-03-31 | $297.94M | $2.28B | $2.23M | $1.42B | $175.79M | 13.08% | 0.10% | 8.08× | Reported |
| 2021-12-31 | $200.08M | $2.29B | $2.44M | $1.43B | $166.14M | 8.74% | 0.11% | 8.61× | Reported |
| 2021-09-30 | $104.04M | $2.29B | $2.78M | $1.59B | $157.01M | 4.55% | 0.12% | 10.14× | Reported |
| 2021-06-30 | $18.64M | $2.24B | $3.12M | $1.80B | $144.13M | 0.83% | 0.14% | 12.48× | Reported |
| 2021-03-31 | $21.29M | $2.19B | $6.14M | $1.46B | $140.89M | 0.97% | 0.28% | 10.39× | Reported |
| 2020-12-31 | $26.29M | $2.12B | $5.43M | $1.60B | $157.06M | 1.24% | 0.26% | 10.16× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $83.04M | $1.81B | $0.00 | $2.62B | $268.57M | 4.58% | 0.00% | 9.77× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $392.61M | $1.79B | $0.00 | $1.36B | $279.96M | 21.87% | 0.00% | 4.87× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |